As fluorouracil, carmofur has been known to induce [[Toxic leukoencephalopathy|leukoencephalopathy]], characterized by progressive damage to white matter in the brain with stroke-like symptome.<ref>{{cite journal |vauthors=Yamada T, Okamura S, Okazaki T |title=Leukoencephalopathy following treatment with carmofur: a case report and review of the Japanese literature |journal=Asia Oceania J Obstet Gynaecol |volume=15 |issue=2 |pages=161–8 |date=June 1989 |pmid=2667512|display-authors=etal}}</ref><ref>{{cite journal |author=Mizutani T |title=[Leukoencephalopathy caused by antineoplastic drugs] |language=Japanese |journal=Brain Nerve |volume=60 |issue=2 |pages=137–41 |date=February 2008 |pmid=18306661}}</ref><ref>{{cite journal |vauthors=Baehring JM, Fulbright RK |title=Delayed leukoencephalopathy with stroke-like presentation in chemotherapy recipients |journal=J Neurol Neurosurg Psychiatry |volume=79 |issue=5 |pages=535–9 |date=May 2008 |pmid=17682013 |doi=10.1136/jnnp.2007.123737}}</ref>

 


 
A clinical trial for small hepatocellular carcinoma was stopped prematurely because 56% of the treated patients had unacceptable side effects. Moreover, the treatment had no survival advantage for stage 1 and 2 cancer patients.<ref name=" Yamamoto 1996 ">{{cite journal |vauthors= Yamamoto M, Arii S, Sugahara K, Tobe T | title = Adjuvant oral chemotherapy to prevent recurrence after curative resection for hepatocellular carcinoma | journal = Br J Surg | volume = 83 | issue = 3 | pages = 336–40 |date=Mar 1996 | pmid = 8665186 | doi=10.1002/bjs.1800830313}}</ref> This may be a reason why carmofur was never pursued for FDA-approval in the US.<ref name=" Shelton 2016"/>

 

